When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
EPZM - FDA OKs Epizyme's tazemetostat for treatment-resistant follicular lymphoma
Epizyme Inc.
Under accelerated review status, the FDA approves Epizyme's (EPZM+4.5%) Tazverik (tazemetostat) for the treatment of adult patients with relapsed/refractory follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least two prior systemic therapies and adults with relapsed/refractory FL who have no realistic treatment options.
More news on: Epizyme, Inc., Healthcare stocks news, Stocks on the move,